Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
4.915
+0.025 (0.51%)
At close: Aug 13, 2025, 4:00 PM
4.910
-0.005 (-0.10%)
After-hours: Aug 13, 2025, 4:20 PM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $101.01M in the quarter ending June 30, 2025, a decrease of -22.44%. This brings the company's revenue in the last twelve months to $429.53M, down -4.21% year-over-year. In the year 2024, Organogenesis Holdings had annual revenue of $482.04M with 11.29% growth.
Revenue (ttm)
$429.53M
Revenue Growth
-4.21%
P/S Ratio
1.47
Revenue / Employee
$494,282
Employees
869
Market Cap
623.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ORGO News
- 5 days ago - Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 22 days ago - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 4 weeks ago - Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation - GlobeNewsWire
- 2 months ago - Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario - Seeking Alpha
- 3 months ago - Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - GlobeNewsWire